Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Candida haemulonii is now considered a complex of two species and one variety: C. haemulonii sensu stricto, Candida duobushaemulonii and the variety C. haemulonii var. vulnera. Identification (ID) of these species is relevant for epidemiological purposes and for therapeutic management, but the different phenotypic commercial systems are unable to provide correct species ID for these emergent pathogens. Hence, we evaluated the MALDI-TOF MS performance for the ID of C. haemulonii species, analyzing isolates/strains of C. haemulonii complex species, Candida pseudohaemulonii and Candida auris by two commercial platforms, their databases and softwares. To differentiate C. haemulonii sensu sctricto from the variety vulnera, we used the ClinProTools(TM) models and a single-peak analysis with the software FlexAnalysis(TM). The Biotyper(TM) database gave 100% correct species ID for C. haemulonii sensu stricto, C. pseudohaemulonii and C. auris, with 69% of correct species ID for C. duobushaemulonii. Vitek MS(TM) IVD database gave 100% correct species ID for C. haemulonii sensu stricto, misidentifying all C. duobushaemulonii and C. pseudohaemulonii as C. haemulonii, being unable to identify C. auris. The Vitek MS(TM) RUO database needed to be upgraded with in-house SuperSpectra to discriminate C. haemulonii sensu stricto, C. duobushaemulonii, C. pseudohaemulonii, and C. auris strains/isolates. The generic algorithm model from ClinProTools(TM) software showed recognition capability of 100% and cross validation of 98.02% for the discrimination of C. haemulonii sensu stricto from the variety vulnera. Single-peak analysis showed that the peaks 5670, 6878, or 13750 m/z can distinguish C. haemulonii sensu stricto from the variety vulnera.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909767 | PMC |
| http://dx.doi.org/10.3389/fmicb.2016.00940 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phenotypic and Molecular Characterization of Multidrug-Resistant Clinical Isolates of the Species Complex (Formerly Species Complex) from the Brazilian Amazon Reveals the First Case of in Brazil.
J Fungi (Basel)
May 2025
Laboratório de Micoses Superficiais e Sistêmicas, Seção de Bacteriologia e Micologia, Instituto Evandro Chagas, Ananindeua 67030-000, Pará, Brazil.
This study included 24 isolates of the species complex from patients in the Brazilian Amazon between 2021 and 2024. These isolates were identified by sequencing as (54.2%), sensu stricto (29.
View Article and Find Full Text PDFThe multidrug-resistant complex and phylogenetic related species: Insights into antifungal resistance mechanisms.
Curr Res Microb Sci
January 2025
Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brasil.
The rise of multidrug-resistant (MDR) fungal pathogens poses a serious global threat to human health. Of particular concern are , the complex (which includes C and var. ), and phylogenetically related species, including and .
View Article and Find Full Text PDFRepurposing tafenoquine as a potent antifungal agent against Candida haemulonii sensu stricto.
J Antimicrob Chemother
May 2025
Health Sciences Research Laboratory, Federal University of Grande Dourados, Cidade Universitária, Rodovia Dourados-Itahum km 12, CEP: 79804970, Dourados, Mato Grosso do Sul, Brazil.
Background: The rise in fungal infections caused by multidrug-resistant pathogens like Candida haemulonii sensu stricto presents a significant global health challenge. The common resistance to current treatments underscores the urgency to explore alternative therapeutic strategies, including drug repurposing.
Objectives: To assess the potential of repurposing tafenoquine, an antimalarial agent, for antifungal use against C.
Insight into Virulence and Mechanisms of Amphotericin B Resistance in the Complex.
J Fungi (Basel)
August 2024
Department of Laboratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
Article Synopsis
- The text discusses a group of emerging human fungal pathogens that are resistant to multiple drugs and have been increasingly isolated in countries like China, Malaysia, and Brazil.
- These fungi utilize various strategies, such as biofilm formation and immune evasion, to infect hosts and cause disease, along with a concerning resistance to antifungal treatments like amphotericin B (AMB).
- The review aims to enhance our understanding of these fungi's virulence factors, how AMB works against them, and why they are resistant to this common antifungal medication.
Cell Aggregation Capability of Clinical Isolates from and Species Complex.
Trop Med Infect Dis
July 2023
Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.
The opportunistic fungal pathogens belonging to the complex and the phylogenetically related species are well-known for causing infections that are difficult to treat due to their multidrug-resistance profiles. is even more worrisome due to its ability to cause outbreaks in healthcare settings. These emerging yeasts produce a wide range of virulence factors that facilitate the development of the infectious process.
View Article and Find Full Text PDF